Rare Neurological Disease Treatment Industry Set to Skyrocket, Projected to Reach a US$ 19.795 Billion Horizon by 2032-FMI Report

The majority of rare diseases currently have no or few effective diagnostic and treatment procedures, which can be attributed in part to a lack of funding for research on rare disease pathogenesis and a lack of representative patients. rare neurological disease treatment industry are one of the most common types of rare diseases, with ineffective diagnoses and treatment options. According to the WHO, one out of every ten people will be diagnosed with a rare neurological disorder during their lifetime. Brain diseases are regarded as one of the major determinants of neurological disease prevalence around the world, with early intervention being the only way to prevent or reduce long-term morbidity and associated healthcare costs.

New Drug Formulations and Initiatives toward Improving Treatment & Care of Patients to Influence Market Growth

Declining blockbuster drugs have led pharmaceutical companies to keenly investigate potential new areas of research & development. Drug manufacturers have been incentivized by the Orphan Drug Act to develop new drug formulations associated with treatment of various rare diseases such as rare neurological diseases, in a bid to introduce new treatment options to the market. Regulatory advantages such as breakthrough designations, longer market exclusivity, and reduced fees & tax incentives have encouraged investments in R&D of drugs related to rare neurological diseases.

Get a Sample Copy of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-6445

The world is entering into a new era, wherein science has realized the capability of aiding development of treatment & care for patients affected with rare neurological conditions. Several initiatives are being taken for coordinating efforts of pharmaceutical companies and healthcare institutes who share similar aim of improving treatment & care for patients suffering from rare neurological diseases.

For example, Brains for Brain Foundation, European Brain Council, LSD Patient Collaborative, and members of pharma industry are supporting an initiative in Europe which is expected to enhance visibility, awareness and recognition of rare neurological disorders for facilitating their early diagnosis. The initiative also aims to facilitate and promote collaboration and partnership between physicians, patient advocates, decision- & policy-makers, and researchers.

North America to Lead Global Rare Neurological Disease Treatment Market

North America is set to lead the global rare neurological disease treatment market, with an estimated revenue share of over 40% during 2017 to 2026. Economic and technological vigour, coupled with increasing geriatric population in the region, which is highly prone to such brain-related diseases, will influence demand for rare neurological disease treatment in North America.

The market revenue share of Europe and Asia-Pacific excluding Japan will also remain significant. However, combined revenues from the markets in these two regions will continue to be smaller than those amassed from the market in North America. Rare neurological disease treatment market in North America and Europe will record a parallel expansion through 2026, in terms of value.

Biologics to Remain Preferred Drug for Rare Neurological Disease Treatment

Biologics will continue to be the preferred drug for treatment of rare neurological diseases. Revenues from sales of biologics will account for the lion’s share of the market through the forecast period, based on drug type. However, revenues from sales of organic compounds for rare neurological disease treatment are forecast to record a relatively faster growth through 2026.

With an estimated market revenue share of nearly 60% during 2017 to 2026, Alzhiemer’s disease will continue to dominate the market, based on indication. In addition, revenues from treatment of this indication segment are likely to record the fastest rise in the market through 2026. Injectables will remain sought-after among mode of administration of drugs for treating rare neurological conditions.

Since the recent past, leading pharmaceutical companies have been placing more emphasis on rare disease, with tremendous support from the government. There is a greater likelihood that effective therapeutic measures for these life threatening rare diseases will be realized in the near future.

Key Players:

• EMD Serono, Inc.
• Jazz Pharmaceuticals
• Teva Pharmaceutical Industries Limited
• Johnson & Johnson
• Sanofi
• Medtronic Plc
• Bayer Aktiengesellschaft
• Novartis AG.

Key Segments :

By Vehicle Type:

• Passenger cars
• Light commercial Vehicles
• Heavy Commercial Vehicles

By Fuel Type:

• Petrol
• Diesel

By Tuning stage:

• Stage 1
• Stage 2
• Stage 3

By Tuning Method:

• OBD Ports
• Bench Tuning

By Application:

• Racing
• Fuel Economizing
• Performance tuning

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia & Pacific
• Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube